Discontinued — last reported Q4 '25
Operating
D&A
Abbott D&A decreased by 0.3% to $370.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.2%, from $342.00M to $370.00M. Over 4 years (FY 2021 to FY 2025), D&A shows relatively stable performance with a -1.0% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ4 2025Feb 20, 2026
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
Metric ID:
depreciation_and_amortization_cfHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $370.00M | $327.00M | $369.00M | $311.00M | $315.00M | $317.00M | $311.00M | $315.00M | $302.00M | $328.00M | $332.00M | $333.00M | $334.00M | $331.00M | $342.00M | $336.00M | $357.00M | $371.00M | $370.00M |
| QoQ Change | — | -11.6% | +12.8% | -15.7% | +1.3% | +0.6% | -1.9% | +1.3% | -4.1% | +8.6% | +1.2% | +0.3% | +0.3% | -0.9% | +3.3% | -1.8% | +6.3% | +3.9% | -0.3% |
| YoY Change | — | — | — | — | -14.9% | -3.1% | -15.7% | +1.3% | -4.1% | +3.5% | +6.8% | +5.7% | +10.6% | +0.9% | +3.0% | +0.9% | +6.9% | +12.1% | +8.2% |
Range$302.00M – $371.00M
CAGR+0.0%
Avg YoY Growth+1.5%
Median YoY Growth+3.0%
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Diagnostic Products | $129.00M | $129.00M | $134.00M | $126.00M | $135.00M | $136.00M | $136.00M | $144.00M |
| Medical Devices | $87.00M | $87.00M | $82.00M | $88.00M | $94.00M | $97.00M | $99.00M | $100.00M |
| Nutritional Products | $39.00M | $38.00M | $43.00M | $42.00M | $44.00M | $47.00M | $42.00M | $50.00M |
| Established Pharmaceuticals | $24.00M | $23.00M | $25.00M | $23.00M | $25.00M | $28.00M | $25.00M | $30.00M |
| Total | $334.00M | $331.00M | $342.00M | $336.00M | $357.00M | $371.00M | $370.00M | — |
D&A at Other Companies
Frequently Asked Questions
- What is Abbott's d&a?
- Abbott (ABT) reported d&a of $370.00M in Q4 2025.
- How has Abbott's d&a changed year-over-year?
- Abbott's d&a increased by 8.2% year-over-year, from $342.00M to $370.00M.
- What is the long-term trend for Abbott's d&a?
- Over 4 years (2021 to 2025), Abbott's d&a has grown at a -1.0% compound annual growth rate (CAGR), from $1.49B to $1.43B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.